Shun Hu,Liding Zhang,Ying Su,Xiaohan Liang,Jie Yang,Qingming Luo,Haiming Luo
Blood exosomes are emerging as potential biomarkers for diagnosing brain diseases such as Alzheimer’s disease (AD). There is currently a lack of an ultrasensitive technology for identifying core AD biomarkers in blood exosomes to optimize the utility of biomarkers in clinical practice. Here, an immunomagnetic exosomal polymerase chain reaction (iMEP) platform was developed using DNA-conjugated antibodies for the rapid detection of amyloid-β (Aβ1–40 and Aβ1–42) and phosphorylated tau (p-tau396,404 and p-tau181) in clinical blood exosomes. The toehold shift–mediated DNA affinity pulldown eliminates the high detection background, which allows the detection of biomarkers at concentrations down to 10 femtograms per milliliter. With the iMEP assay, exosomal Aβ1–42 was more accurate in differentiating patients with AD from healthy individuals compared with exosomal p-tau181 and p-tau396,404, with a sensitivity of 95.0% and a specificity of 95.0%. The iMEP technique is also adept at quantifying the levels of different exosomal biomarkers associated with disease pathogenesis.
A facile one-pot approach for synthesis of gold nanoparticles with narrow size distribution and good stability was presented by reducing chloroauric acid with a polysaccharide, konjac glucomannan (KGM) in alkaline solution, which is green and economically viable. Here, KGM served both as reducing agent and stabilizer. The effects of KGM on the formation and stabilization of as-synthesized gold nanoparticles were studied systematically by a combination of UV-visible (UV-vis) absorption spectroscopy, transmission electron microscopy, X-ray diffraction, dynamic light scattering, and Fourier transform infrared spectroscopy. Furthermore, the gold nanoparticles exhibited a notable catalytic activity toward the reduction of 4-nitrophenol to 4-aminophenol.
危险品化学品经营许可证（带存储）